Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Biotechnology Stocks Profiles

View company profiles of publicly traded biotechnology stocks, and biotech-related stocks.
Sun, Jul 14th, 2024

Biotechnology (biotech) stocks are publicly traded companies that develop pharmaceutical drugs used in the treatment of disease. You can use Barchart's Biotech Stocks list to find investment opportunities and compare stocks involved in this hot industry.

Relay Therapeutics Inc (RLAY)

Full Profile

Relay Therapeutics Inc. is a clinical-stage precision medicines company. It focuses on enhancing small molecule therapeutic discovery in targeted oncology. The company's product pipeline consist RLY-1971, RLY-4008 and RLY-PI3K1047 which are in clinical stage. Relay Therapeutics Inc. is based in Cambridge, Massachusetts.

52-Week Low
52-Week High
5.70
13.30

Overview:

Market Capitalization, $K 1,093,794
Shares Outstanding, K 132,742
Last Quarter Sales 10,010 K
Last Quarter Net Income -81,390 K
% Insider Shareholders 4.32%
% Institutional Shareholders 96.98%

Ligand Pharm (LGND)

Full Profile

Ligand, being a biotechnology company, focuses on developing/acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand's Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties. Captisol is a well validated chemically modified cyclodextrin that is designed to improve safety and solubility, stability, and bioavailability or lessen the volatility, irritation, smell or taste of drugs. Ligand has merged with CyDex. By this, it added an antibody-generating platform, OmniAb, to the company's portfolio. Its other technology platforms include antigen discovery platform & protein expression platform. All these technologies have created a strong platform for Ligand to seek new licenses and partnerships. Ligand has partnership agreements with leading healthcare companies like Novartis, Amgen, Merck, Pfizer, Celgene, Gilead & Lilly, etc. The company continues to buy smaller companies to increase its technology platforms.

52-Week Low
52-Week High
49.24
100.69

Overview:

Market Capitalization, $K 1,789,380
Shares Outstanding, K 18,000
Last Quarter Sales 30,980 K
Last Quarter Net Income 86,140 K
% Insider Shareholders 5.90%
% Institutional Shareholders 91.28%

Edgewise Therapeutics Inc (EWTX)

Full Profile

Edgewise Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing orally bioavailable, small molecule therapies for rare muscle disorders. Edgewise Therapeutics Inc. is based in Boulder, United States.

52-Week Low
52-Week High
5.12
23.23

Overview:

Market Capitalization, $K 2,094,006
Shares Outstanding, K 93,399
Last Quarter Sales 0 K
Last Quarter Net Income -28,530 K
% Insider Shareholders 24.11%
% Institutional Shareholders N/A

Adaptive Biotechnologies Corp (ADPT)

Full Profile

Adaptive Biotechnologies Corporation is a commercial-stage biotech company. It develops and commercializes immune-driven clinical products to transform the diagnosis and treatment of disease. The company's product pipeline includes immunoSEQ, clonoSEQ and cellular therapy which are in clinical stage. Adaptive Biotechnologies Corporation is based in Seattle, Washington.

52-Week Low
52-Week High
2.28
8.51

Overview:

Market Capitalization, $K 589,472
Shares Outstanding, K 147,368
Last Quarter Sales 41,870 K
Last Quarter Net Income -47,510 K
% Insider Shareholders 6.20%
% Institutional Shareholders 99.17%

Vanda Pharmaceuticals (VNDA)

Full Profile

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial.

52-Week Low
52-Week High
3.30
6.75

Overview:

Market Capitalization, $K 344,532
Shares Outstanding, K 58,198
Last Quarter Sales 47,460 K
Last Quarter Net Income -4,150 K
% Insider Shareholders 7.70%
% Institutional Shareholders 88.14%

Springworks Therapeutics Inc (SWTX)

Full Profile

SpringWorks Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing life-changing medicines for patients with severe rare diseases and cancer. The company's product pipeline consists of Nirogacestat and Mirdametinib which are in clinical stage. SpringWorks Therapeutics Inc. is based in Stamford, United States.

52-Week Low
52-Week High
18.00
53.92

Overview:

Market Capitalization, $K 3,070,124
Shares Outstanding, K 74,086
Last Quarter Sales 21,010 K
Last Quarter Net Income -87,390 K
% Insider Shareholders 7.61%
% Institutional Shareholders N/A

Incyte Corp (INCY)

Full Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor, approved in the United States for the treatment of patients with polycythemia vera ('PV'),who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. The drug is also approved in the United States for treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients aged 12 years or older.

52-Week Low
52-Week High
50.27
67.36

Overview:

Market Capitalization, $K 14,294,280
Shares Outstanding, K 224,541
Last Quarter Sales 880,890 K
Last Quarter Net Income 169,550 K
% Insider Shareholders 17.50%
% Institutional Shareholders 96.97%

Acadia Pharmaceutica (ACAD)

Full Profile

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. The company's sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. The company suffered a setback when the FDA issued a complete response letter to the supplemental new drug application for Nuplazid for treating dementia-related psychosis. Acadia resubmitted the supplemental new drug application to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis. Notably, several additional studies on Nuplazid n targeting different CNS indications, such as'dementia-related psychosis, schizophrenia inadequate response, schizophrenia negative symptoms and as an adjunctive treatment of major depressive disorder (MDD) are currently underway.

52-Week Low
52-Week High
14.55
33.99

Overview:

Market Capitalization, $K 2,935,977
Shares Outstanding, K 165,221
Last Quarter Sales 205,830 K
Last Quarter Net Income 16,560 K
% Insider Shareholders 28.30%
% Institutional Shareholders 96.71%

Novavax Inc (NVAX)

Full Profile

Novavax, Inc. is a biotechnology company engaged in developing innovative vaccines to prevent serious infectious diseases. The company is also developing proprietary immune stimulating saponin-based adjuvants, namely Matrix-M, which already enhanced immune responses and were well-tolerated in multiple studies.'Novavax developed its own coronavirus vaccine NVX-CoV2373. The company is currently marketing two versions of NVX-CoV2373, one marketed in partnership with the Serum Institute of India under the trade name Covovax and another version produced by Novavax and marketed under the trade name Nuvaxovid.'Novavax developed NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with Matrix M adjuvant for senior patients aged 65 years and above.'ResVax a respiratory syncytial virus vaccine is being developed to protect infants by immunizing mothers against the disease. Novavax is discussing the opportunity to bring ResVax to the market globally with the help of commercial partners.

52-Week Low
52-Week High
3.53
23.86

Overview:

Market Capitalization, $K 1,840,696
Shares Outstanding, K 140,404
Last Quarter Sales 93,860 K
Last Quarter Net Income -147,550 K
% Insider Shareholders 0.90%
% Institutional Shareholders 53.04%

Vir Biotechnology Inc (VIR)

Full Profile

Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The company's development pipeline consists of product candidates targeting the hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. Vir Biotechnology Inc. is based in San Francisco, United States.

52-Week Low
52-Week High
7.61
23.87

Overview:

Market Capitalization, $K 1,274,873
Shares Outstanding, K 136,059
Last Quarter Sales 56,380 K
Last Quarter Net Income -65,280 K
% Insider Shareholders 15.60%
% Institutional Shareholders 65.32%

Kiniksa Pharmaceuticals International Plc (KNSA)

Full Profile

Kiniksa Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa Pharmaceuticals Ltd. is based in Massachusetts, United States.

52-Week Low
52-Week High
13.83
22.12

Overview:

Market Capitalization, $K 1,504,637
Shares Outstanding, K 70,940
Last Quarter Sales 79,860 K
Last Quarter Net Income -17,700 K
% Insider Shareholders 54.57%
% Institutional Shareholders 53.95%

Crispr Therapeutics Ag (CRSP)

Full Profile

CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases.

52-Week Low
52-Week High
37.55
91.10

Overview:

Market Capitalization, $K 4,916,752
Shares Outstanding, K 84,918
Last Quarter Sales 500 K
Last Quarter Net Income -116,590 K
% Insider Shareholders 4.10%
% Institutional Shareholders 69.20%

Illumina Inc (ILMN)

Full Profile

Illumina Inc. is a life sciences company, which provides tools and integrated systems for analysis of genetic variation and function. Using its proprietary technologies, the company provides innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, and gene expression profiling of DNA and RNA. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Illumina generates revenue from two segments - Product and Service. Product are primarily attributed to the partnerships and collaborations to develop distributable clinical in-vitro diagnostics for Illumina sequencers. Service include genotyping and sequencing services as well as instrument maintenance contracts.

52-Week Low
52-Week High
89.00
195.64

Overview:

Market Capitalization, $K 18,493,136
Shares Outstanding, K 159,300
Last Quarter Sales 1,076 M
Last Quarter Net Income -126,000 K
% Insider Shareholders 0.17%
% Institutional Shareholders 89.42%

Amgen Inc (AMGN)

Full Profile

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two next-generation products, Aranesp & Neulasta and also a biosimilar drug, Prolia/Xgeva. The acquisition of Immunex Corp gave Amgen access to the multi-blockbuster drug, Enbrel. Other products are Repatha, Blincyto, Parsabiv, Evenity, Aimovig, Lumakras/Lumykras, Kanjinti, Mvasi & Amgevita biosimilars. Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. The erythropoiesis-stimulating agents and granulocyte colony-stimulating factor franchise comprise Epogen/Aranesp and Neupogen/Neulasta respectively. Biosimilar drugs are also a key part of Amgen's growth strategy.

52-Week Low
52-Week High
224.34
333.85

Overview:

Market Capitalization, $K 177,468,784
Shares Outstanding, K 536,435
Last Quarter Sales 7,447 M
Last Quarter Net Income -113,000 K
% Insider Shareholders 0.69%
% Institutional Shareholders 76.50%

Regeneron Pharmaceuticals (REGN)

Full Profile

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV. REGEN-COV is a cocktail of two monoclonal antibodies and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has a collaboration agreement with Roche for the same. While Regeneron has co-developed Eylea with Bayer's HealthCare unit, Praluent was co-developed with Sanofi. Regeneron collaborated with Bayer for the joint development and commercialization of co-formulated combinations of Eylea, rinucumab and nesvacumab for the treatment of ocular diseases or disorders outside the United States.

52-Week Low
52-Week High
715.22
1,106.16

Overview:

Market Capitalization, $K 121,210,096
Shares Outstanding, K 110,186
Last Quarter Sales 3,145 M
Last Quarter Net Income 722,000 K
% Insider Shareholders 7.48%
% Institutional Shareholders 83.31%

Rogers Corp (ROG)

Full Profile

Rogers Corporation is a global leader in engineered materials to power, protect, and connect their world. With more than 180 years of materials science experience, Rogers delivers high-performance solutions that enable clean energy, internet connectivity, and safety and protection applications, as well as other technologies where reliability is critical. Rogers delivers Power Electronics Solutions for energy-efficient motor drives, e-Mobility and renewable energy; Elastomeric Material Solutions for sealing, vibration management and impact protection in mobile devices, transportation interiors, industrial equipment and performance apparel; and Advanced Connectivity Solutions for wireless infrastructure, automotive safety and radar systems. Headquartered in Arizona (USA), Rogers operates manufacturing facilities in the United States, China, Germany, Belgium, Hungary, and South Korea, with joint ventures and sales offices worldwide.

52-Week Low
52-Week High
105.48
173.16

Overview:

Market Capitalization, $K 2,353,766
Shares Outstanding, K 18,657
Last Quarter Sales 213,400 K
Last Quarter Net Income 7,800 K
% Insider Shareholders 1.35%
% Institutional Shareholders 96.02%

Biontech Se ADR (BNTX)

Full Profile

BioNTech SE is a biotechnology company. It develops and commercializes immunotherapies for cancer and other diseases. BioNTech SE is based in Mainz, Germany.

52-Week Low
52-Week High
78.02
125.83

Overview:

Market Capitalization, $K 20,194,822
Shares Outstanding, K 237,726
Last Quarter Sales 203,680 K
Last Quarter Net Income -342,100 K
% Insider Shareholders 19.20%
% Institutional Shareholders 15.52%

Gilead Sciences Inc (GILD)

Full Profile

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.

52-Week Low
52-Week High
62.07
87.86

Overview:

Market Capitalization, $K 87,159,880
Shares Outstanding, K 1,245,853
Last Quarter Sales 6,686 M
Last Quarter Net Income -4,170 M
% Insider Shareholders 0.16%
% Institutional Shareholders 83.67%

Biomarin Pharmaceuticals (BMRN)

Full Profile

BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder), Vimizim , Brineura, Palynziq and Voxzogo. BioMarin has a collaboration agreement with Sanofi's subsidiary Genzyme for Aldurazyme. Genzyme is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.'The newest drug in BioMarin's portfolio, Voxzogo for treating achondroplasia, the most common form of dwarfism. BioMarin's biologics license application (BLA) for Roctavian/valoctocogene roxaparvovec (valrox), a gene therapy for severe hemophilia A, was given a complete response letter (CRL) by the FDA.

52-Week Low
52-Week High
73.68
99.56

Overview:

Market Capitalization, $K 16,143,598
Shares Outstanding, K 189,880
Last Quarter Sales 648,830 K
Last Quarter Net Income 88,660 K
% Insider Shareholders 1.85%
% Institutional Shareholders 98.71%

Sanofi-Aventis S.A. ADR (SNY)

Full Profile

Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.

52-Week Low
52-Week High
42.63
55.72

Overview:

Market Capitalization, $K 130,004,832
Shares Outstanding, K 2,532,726
Last Quarter Sales 12,071 M
Last Quarter Net Income 1,230 M
% Insider Shareholders 1.00%
% Institutional Shareholders 10.04%

Novartis Ag ADR (NVS)

Full Profile

Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.

52-Week Low
52-Week High
92.19
112.48

Overview:

Market Capitalization, $K 228,314,800
Shares Outstanding, K 2,044,000
Last Quarter Sales 12,120 M
Last Quarter Net Income 2,688 M
% Insider Shareholders 0.01%
% Institutional Shareholders 13.12%

Vertex Pharmaceutic (VRTX)

Full Profile

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which are collectively approved to treat the people with CF in North America, Europe and Australia. Trikafta, Vertex's triple combination regimen, was approved by the FDA for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency and muscular dystrophies. Pimodivir/VX-787, for the treatment of influenza, was out-licensed to Janssen while oncology candidates VX-970, VX-984 and VX-803 were divested to Merck KGaA.

52-Week Low
52-Week High
340.20
496.71

Overview:

Market Capitalization, $K 126,120,832
Shares Outstanding, K 258,053
Last Quarter Sales 2,691 M
Last Quarter Net Income 1,100 M
% Insider Shareholders 0.20%
% Institutional Shareholders 90.96%

Moderna Inc (MRNA)

Full Profile

Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency use in several countries as COVID-19 vaccine. The company has also developed booster doses of its COVID-19 vaccine and is developing variant-specific booster candidates.

52-Week Low
52-Week High
62.55
170.47

Overview:

Market Capitalization, $K 46,548,328
Shares Outstanding, K 383,240
Last Quarter Sales 167,000 K
Last Quarter Net Income -1,175 M
% Insider Shareholders 15.70%
% Institutional Shareholders 75.33%

Astrazeneca Plc ADR (AZN)

Full Profile

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.

52-Week Low
52-Week High
60.47
80.86

Overview:

Market Capitalization, $K 245,684,560
Shares Outstanding, K 3,100,512
Last Quarter Sales 12,679 M
Last Quarter Net Income 2,180 M
% Insider Shareholders N/A
% Institutional Shareholders 20.35%

Johnson & Johnson (JNJ)

Full Profile

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.

52-Week Low
52-Week High
143.13
175.97

Overview:

Market Capitalization, $K 360,713,024
Shares Outstanding, K 2,406,679
Last Quarter Sales 21,383 M
Last Quarter Net Income 3,255 M
% Insider Shareholders 0.16%
% Institutional Shareholders 69.55%

United Therapeutic (UTHR)

Full Profile

United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets.

52-Week Low
52-Week High
208.62
330.00

Overview:

Market Capitalization, $K 14,255,129
Shares Outstanding, K 44,356
Last Quarter Sales 677,700 K
Last Quarter Net Income 306,600 K
% Insider Shareholders 12.50%
% Institutional Shareholders 94.08%

Bristol-Myers Squibb Company (BMY)

Full Profile

Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.

52-Week Low
52-Week High
39.35
65.38

Overview:

Market Capitalization, $K 82,016,464
Shares Outstanding, K 2,027,100
Last Quarter Sales 11,865 M
Last Quarter Net Income -11,911 M
% Insider Shareholders 0.09%
% Institutional Shareholders 76.41%

Biogen Inc (BIIB)

Full Profile

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).

52-Week Low
52-Week High
189.44
281.12

Overview:

Market Capitalization, $K 33,496,044
Shares Outstanding, K 145,597
Last Quarter Sales 2,291 M
Last Quarter Net Income 393,400 K
% Insider Shareholders 0.16%
% Institutional Shareholders 87.93%

Abbvie Inc (ABBV)

Full Profile

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.

52-Week Low
52-Week High
132.70
182.89

Overview:

Market Capitalization, $K 300,692,000
Shares Outstanding, K 1,765,868
Last Quarter Sales 12,310 M
Last Quarter Net Income 1,369 M
% Insider Shareholders 0.25%
% Institutional Shareholders 70.23%

Ascendis Pharma ADR (ASND)

Full Profile

Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark.

52-Week Low
52-Week High
85.29
161.00

Overview:

Market Capitalization, $K 8,040,536
Shares Outstanding, K 58,231
Last Quarter Sales 104,110 K
Last Quarter Net Income -142,260 K
% Insider Shareholders 40.00%
% Institutional Shareholders N/A

Merck & Company (MRK)

Full Profile

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.

52-Week Low
52-Week High
99.14
134.63

Overview:

Market Capitalization, $K 323,591,296
Shares Outstanding, K 2,532,806
Last Quarter Sales 15,775 M
Last Quarter Net Income 4,762 M
% Insider Shareholders 0.09%
% Institutional Shareholders 76.07%

Gsk Plc ADR (GSK)

Full Profile

GSK plc is a biopharma company. Its vaccine portfolio protects people from meningitis, shingles, flu, polio, measles and many more. GSK plc, formerly known as GLAXOSMITHKLINE, is based in Brentford, the United Kingdom.

52-Week Low
52-Week High
33.67
45.92

Overview:

Market Capitalization, $K 81,158,392
Shares Outstanding, K 2,072,482
Last Quarter Sales 9,337 M
Last Quarter Net Income 1,326 M
% Insider Shareholders 10.00%
% Institutional Shareholders 15.74%

Abbott Laboratories (ABT)

Full Profile

Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson.

52-Week Low
52-Week High
89.67
121.64

Overview:

Market Capitalization, $K 181,304,656
Shares Outstanding, K 1,739,634
Last Quarter Sales 9,964 M
Last Quarter Net Income 1,225 M
% Insider Shareholders 1.10%
% Institutional Shareholders 75.18%
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar